Asthma Exacerbation — Adult

Key Points

• A quiet chest, exhaustion, confusion, or rising carbon dioxide can indicate life-threatening asthma.
• Treat immediately with repeated inhaled SABA and add ipratropium in severe exacerbations.
• Give systemic corticosteroid early rather than waiting for bronchodilator failure.
• Use IV magnesium for severe or poorly responsive exacerbations.
• Do not prescribe antibiotics routinely without evidence of bacterial infection.
• Chest radiography and blood gas testing are selective, not mandatory in every attack.
• SABA-only long-term asthma treatment is not recommended; discharge therapy should include inhaled corticosteroid.
• Intubation requires a strategy that minimizes dynamic hyperinflation and barotrauma.

Algorithm

1. Assess for life-threatening features, oxygenation, speech, mental status, accessory-muscle use, and ability to measure PEF or FEV1.
2. Start repeated inhaled SABA; add ipratropium for severe disease and provide oxygen if hypoxemic.
3. Give systemic corticosteroid early and identify anaphylaxis or another alternative emergency.
4. Reassess after initial bronchodilator therapy using symptoms, exam, oxygenation, and airflow measurement when possible.
5. For severe or incomplete response, continue bronchodilators and give IV magnesium; obtain selective imaging or blood gas testing when indicated.
6. Escalate immediately for fatigue, worsening mental status, persistent hypoxemia, or rising PaCO2; involve critical care and prepare for high-risk ventilation if necessary.
7. Once stable, observe for sustained improvement and step down bronchodilator frequency.
8. Discharge only with ICS-containing controller or anti-inflammatory reliever therapy, inhaler teaching, action plan, and follow-up.

Clinical Synopsis & Reasoning

Assess severity immediately from speech, respiratory rate, accessory-muscle use, mental status, oxygen saturation, heart rate, and objective airflow when feasible. Peak expiratory flow or FEV1 can quantify obstruction but should not delay treatment in a distressed patient. A patient who cannot speak in full sentences, is agitated or drowsy, has marked accessory-muscle use, a silent chest, cyanosis, or poor respiratory effort may be near respiratory failure even if wheeze diminishes. Common triggers include viral infection, allergen exposure, smoke or vaping, poor adherence to inhaled corticosteroid-containing therapy, occupational exposure, and medications such as nonselective beta blockers or NSAIDs in susceptible patients. Consider pneumonia, pneumothorax, pulmonary embolism, heart failure, inducible laryngeal obstruction, and anaphylaxis when findings are atypical. Chest radiography is not routine for a typical uncomplicated exacerbation but is appropriate for focal findings, fever with concern for pneumonia, chest pain, trauma, suspected pneumothorax, or poor response. Blood gas testing is reserved for severe or deteriorating disease; a normal or rising PaCO2 in a patient working hard to breathe is ominous because early asthma usually produces hypocapnia. The 2026 GINA strategy continues to emphasize that every patient with asthma should receive inhaled corticosteroid-containing treatment rather than SABA-only chronic therapy.

Treatment Strategy & Disposition

Give repeated inhaled short-acting beta-2 agonist promptly, using a pressurized metered-dose inhaler with spacer or nebulization according to severity and patient ability. Add inhaled ipratropium for severe exacerbations because combined bronchodilation reduces admission risk. Give systemic corticosteroid early, typically prednisone or prednisolone 40 to 50 mg daily for about 5 to 7 days in adults, or an equivalent regimen, unless a patient-specific contraindication requires modification. Titrate oxygen to correct hypoxemia while avoiding unnecessary hyperoxia. IV magnesium sulfate is useful in severe attacks with poor initial response or very low lung function. Epinephrine is not routine asthma therapy but is required for concomitant anaphylaxis and can be considered in special circumstances when inhaled therapy cannot be delivered. Antibiotics are not routine unless there is convincing bacterial infection. Noninvasive ventilation has uncertain routine benefit and should never delay intubation in a patient with worsening exhaustion or altered consciousness. Intubation is high risk because severe airflow obstruction causes dynamic hyperinflation and hypotension; use an experienced airway team, adequate induction, low respiratory rate, prolonged expiratory time, permissive hypercapnia, and careful monitoring for auto-PEEP. Before discharge, confirm sustained improvement, prescribe an ICS-containing regimen, teach inhaler technique, provide a written action plan, and arrange close follow-up.

Epidemiology / Risk Factors

• Viral respiratory infection is a common exacerbation trigger across age groups.
• Prior ICU admission, prior intubation, recent severe exacerbation, frequent SABA use, poor ICS adherence, and psychosocial barriers increase risk of fatal asthma.
• Smoking and vaping worsen control and treatment response.
• Occupational asthma can present as recurrent work-related exacerbations.
• Severe exacerbations may occur in patients whose baseline daily symptoms appear modest.

Investigations

Response by Peak Flow

Pharmacology

Prognosis / Complications

• Most exacerbations improve with timely bronchodilator and corticosteroid therapy.
• Previous near-fatal asthma is one of the strongest predictors of future life-threatening events.
• Failure to improve after intensive initial therapy predicts admission and possible ICU need.
• Post-discharge relapse is reduced by adequate corticosteroid treatment, an ICS-containing regimen, action planning, and early follow-up.
• Frequent exacerbations should prompt reassessment of diagnosis, adherence, inhaler technique, exposures, and eligibility for biologic therapy.

Patient Education / Counseling

• Demonstrate inhaler and spacer technique before discharge rather than relying on verbal instructions alone.
• Provide a written asthma action plan with clear instructions for worsening symptoms and when to seek emergency care.
• Explain why an inhaled corticosteroid-containing regimen is necessary even when symptoms improve.
• Review smoking, vaping, allergen, occupational, and medication triggers.
• Advise urgent emergency care for inability to speak, blue lips, severe breathlessness at rest, faintness, confusion, or poor response to rescue medication.

Notes

The safest discharge plan begins before the patient leaves the treatment area. A patient who improves after repeated albuterol but returns to SABA-only therapy remains at high risk for another attack. Confirm an ICS-containing regimen, observe inhaler technique, supply a spacer when appropriate, and provide a written action plan. Frequent reliever use, repeated steroid bursts, or prior ICU care should trigger expedited specialist review. In a deteriorating attack, do not be reassured by fading wheeze. A quiet chest with exhaustion or rising carbon dioxide reflects critically reduced airflow and impending ventilatory failure.

References

1. GINA 2026 Strategy Report — Link